HER2/EGFR in Cancer Research Peer reviewed

Beyond Cytotoxic Payloads for Antibody Drug Conjugates─A Medicinal Chemistry Perspective

Allan M. Jordan, Stuart Best, Joshua Greally

Bioconjugate Chemistry | Aug 21, 2026

Scollr summary

What this paper is about

Observations around LogD, pKa, permeability, permeability, efflux, and metabolic stability are discussed and design rules and guidelines for the optimization of next-generation ADC payloads are suggested.

Full abstract

Read the full abstract

Abstract Despite significant research and investment, antibody–drug conjugates (ADCs) primarily rely on a limited number of broadly cytotoxic payloads that contribute significantly to toxicity. More recently, there has been a migration toward mechanistically targeted payloads, pairing improved antibodies with small molecules that act on disease-specific biology, improving precision and tolerability. Designing these next-generation payloads means rethinking some of our design metrics and guidelines derived from traditional medicinal chemistry: properties such as LogD, pKa, permeability, efflux, and metabolic stability must be carefully balanced to ensure efficient intracellular release while limiting systemic exposure. Here we discuss our observations around these properties and suggest design rules and guidelines for the optimization of next-generation ADC payloads.

Direct answer

What can I do from this paper page?

Use this page to scan "Beyond Cytotoxic Payloads for Antibody Drug Conjugates─A Medicinal Chemistry Perspective" quickly: start with the summary and abstract, then check the authors, source, topics, and related papers. From here, open Scollr to follow HER2/EGFR in Cancer Research, save the paper, or map adjacent work.

Authors

Researchers on this paper

Allan M. Jordan

first | Medicines Discovery Catapult | ORCID 0000-0003-3449-3993

Stuart Best

middle | Medicines Discovery Catapult

Joshua Greally

last

Research areas

Follow related topics

Citation

BibTeX

@article{Jordan2026Beyond,
  title = {Beyond Cytotoxic Payloads for Antibody Drug Conjugates─A Medicinal Chemistry Perspective},
  author = {Allan M. Jordan and Stuart Best and Joshua Greally},
  journal = {Bioconjugate Chemistry},
  year = {2026},
  doi = {10.1021/acs.bioconjchem.6c00322},
  url = {https://doi.org/10.1021/acs.bioconjchem.6c00322}
}

FAQ

Using this paper in a discovery workflow

How do I find related work for this paper?

Use the related papers and topic links on this page as starting points. In Scollr, you can also open the paper and build a literature map around its references, citing papers, and related work.

How can I keep up with new HER2/EGFR in Cancer Research papers?

Follow HER2/EGFR in Cancer Research in Scollr. New papers from the topic flow into a personalized feed, and you can save useful studies to revisit later.

Can I cite this paper from this page?

This page includes a static BibTeX block for Beyond Cytotoxic Payloads for Antibody Drug Conjugates─A Medicinal Chemistry Perspective. Always verify the DOI, source, and publication details against the publisher record before submitting a manuscript.

Follow this research in Scollr

Follow the topics and authors behind this paper, save useful studies, and build a literature map when you are ready to go deeper.

Get the app